



PTO/SB/21 (04-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|---|------------------------|---------------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | Application Number | 10/060,759 |
| | Filing Date | January 30, 2002 |
| | First Named Inventor | Adam Lerner |
| | Art Unit | 1614 |
| | Examiner Name | SPIVACK, Phyllis G. |
| Total Number of Pages in This Submission | Attorney Docket Number | 701586-50174-DIV |

| ENCLOSURES (Check all that apply) | | |
|--|---|---|
| <input checked="" type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance Communication to Technology Center (TC) |
| <input checked="" type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input checked="" type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation | <input type="checkbox"/> Status Letter |
| <input checked="" type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | Certificate of Mailing; Schwabe and Sheppard References; Check \$55.00; and Return Receipt Postcard |
| <input type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application | Remarks | |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | |
|--|--|
| Firm or Individual name | Ronald I. Eisenstein Nixon Peabody LLP, 100 Summer Street, Boston, MA 02110 |
| Signature | |
| Date | 8/9/04 |

| CERTIFICATE OF TRANSMISSION/MAILING | | |
|---|-------------------|--------------------|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. | | |
| Typed or printed name | Linda M. Ginsberg | |
| Signature | | Date 08/09/2004 |

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Applicant's Docket No. 701586-50174-DIV

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Adam Lerner

Application No.: 10/060,759

Group No.: 1614

Filed: 01/30/2002

Examiner: SPIVACK, Phyllis G.

For: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC
LYMPHOCYTIC LEUKEMIA

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)


I hereby certify that the attached correspondence comprising:

1. Certificate of Mailing (1 pg.);
2. Transmittal Form (1 pg.);
3. Fee Transmittal (1 pg.);
4. Petition for Extension of Time in duplicate (2 pp.);
5. Response to Office Communication (8 pp.);
6. Schwabe Reference (11 pp.);
7. Sheppard Reference (10 pp.);
8. Check \$55.00; and
9. Return Receipt Postcard.

is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on August 9, 2004.

Linda M. Ginsberg

Signature of person mailing paper



Practitioner's Docket No. 701586-50174-DIV

1614
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lerner, Adam
Serial No.: 10/060,759 GROUP: 1614
Filed: January 30, 2002 EXAMINER: SPIVACK, Phyllis
For: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC
LYMPHOCYTIC LEUKEMIA

DIVISIONAL OF:

Applicants: LERNER, Adam
Serial No.: 09/423,349 Group No.: 1614
Filed: November 22, 1999 Examiner: Goldberg, J.
For: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC
LYMPHOCYTIC LEUKEMIA

RESPONSE TO OFFICE COMMUNICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication dated June, 9, 2004, enclosed is a Petition for a One Month Extension of Time and Payment of Fee. Applicant provides the chemical name of Type 4 cyclic adenosine monophosphate diesterase inhibitor XX5, as ((4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone)(Ro-1724)).

Amendments to the Specification begin on page 2 of this paper.

Amendments to the claims begin on page 5 of this paper.

Remarks begin on page 7 of this paper.